INVESTOR RELATIONS

News

Date Title and Summary Additional Formats
Toggle Summary NantKwest and Viracta Therapeutics Announce Series B Financing and Immunotherapy Partnership
by Jen Hodson | Apr 4, 2017 | Press Releases | Culver City and San Diego, CA   April 4, 2017 -  NantKwest, Inc. (Nasdaq:NK) and Viracta Therapeutics, Inc . announced the initial closing of a Series B Preferred financing round of up to $18.4 million with NantKwest, Inc .
View HTML
Toggle Summary NantKwest Announces $50 Million Stock Repurchase Program
CULVER CITY, Calif. --(BUSINESS WIRE)--Nov. 12, 2015-- NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory
View HTML
Toggle Summary NantKwest Announces Achievement of End Point in Merkel Cell Carcinoma Phase II Trial With Evidence of Efficacy of Activated Natural Killer (aNK) Cells in Solid Tumors
Promising Clinically Meaningful Responses Seen Including a Radiological Complete Response in Early Data Analysis Presented at the 31st Annual Meeting of the Society for Immunotherapy of Cancer CULVER CITY, Calif. --(BUSINESS WIRE)--Nov. 14, 2016-- NantKwest Inc.
View HTML
Toggle Summary NantKwest Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
CULVER CITY, Calif. --(BUSINESS WIRE)--Jul. 31, 2015-- NantKwest, Inc. (formerly Conkwest, Inc. ) (Nasdaq: NK), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory
View HTML
Toggle Summary NantKwest Announces Durable Complete Responses in Multiple Advanced-Stage Solid Tumor Cancers Following Off-the-Shelf NK Cell Therapy in First 35 Patients
5 out of 35 Durable Complete Responses Observed in Patients with Relapsed Third-Line Advanced Solid Tumors with Duration Ranging 4 to 24 Months CULVER CITY, Calif. --(BUSINESS WIRE)--Jun. 4, 2019-- Patrick Soon-Shiong , MD, Chairman and CEO of NantKwest (Nasdaq:NK), a leading clinical-stage,
View HTML
Toggle Summary NantKwest Announces Durable Complete Responses in Phase I Trial of aNK Cell Therapy in Patients with Relapsed Hematological Malignancies
42% Of Patents Exhibited A Response, With Two Complete Responses In A Phase 1 Study Of 12 Patients With A Patient In Complete Remission 10 Years After Failing Transplant Therapy For Hodgkin’s Lymphoma, And A Second Patient In Complete Remission 2 Years After Failing Transplant Therapy In Multiply
View HTML
Toggle Summary NantKwest Announces Enhanced High-Affinity Activated Natural Killer (haNK) Cell Therapy in Preclinical Studies of HER2 Positive Breast Cancer at Presentation at the San Antonio Breast Cancer Symposium
CULVER CITY, Calif. --(BUSINESS WIRE)--Dec. 12, 2016-- NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory
View HTML
Toggle Summary NantKwest Announces FDA Grant of Orphan Drug Designation for the Company’s aNK Natural Killer Cell Therapy in Merkel Cell Carcinoma
CULVER CITY, Calif. --(BUSINESS WIRE)--Mar. 20, 2017-- NantKwest, Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory
View HTML
Toggle Summary NantKwest Announces Landmark Study Published on high affinity haNK Cell Therapy in the Journal Oncotarget
Next Generation NK Cell Therapy Poised to Transition into Human Clinical Trials CULVER CITY, Calif. --(BUSINESS WIRE)--Nov. 22, 2016-- NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of the immune system using
View HTML
Toggle Summary NantKwest Announces Launch of Initial Public Offering
CULVER CITY, Calif.--( BUSINESS WIRE )--NantKwest, Inc. (formerly known as Conkwest, Inc.), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using the Natural Killer (NK) cell to treat cancer, infectious diseases and inflammatory diseases, today
View HTML